AN2 Therapeutics Phase 3 EBO-301 misses primary endpoint; outlines boron pipeline milestones, cash runway into 2028

AN2 Therapeutics, Inc.

Phase 3 portion of EBO-301 (n=97) did not meet primary endpoint of QOL-B respiratory domain improvement at month 6.
Cash, cash equivalents & investments $78.5M as of March 31, 2025; cash runway extended into 2028.
Initiated start up for Phase 1 study of AN2-502998 for chronic Chagas disease, expected completion in 2H25.
Plans Phase 2 study for epetraborole in melioidosis in 2H25 aiming to reduce ~40% mortality.
First oncology compounds from boron platform on track for development in 2H25, targeting ENPP1, PI3Kα.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.